Peptide Database

A small molecule NNMT inhibitor studied for metabolic effects. May enhance energy expenditure and reduce fat accumulation through NAD+ pathway modulation.

Synthetic 34-amino-acid analogue of parathyroid hormone-related protein (PTHrP), FDA-approved April 2017 as an anabolic osteoporosis therapy. Selectively activates the transient conformation of the PTH1 receptor, producing strong bone formation with less bone resorption than teriparatide.

A discontinued ActRIIB-Fc fusion protein that acted as a myostatin trap. Development halted in 2011 due to bleeding-related safety concerns.

Synthetic acetylated hexapeptide developed by Lipotec / Lubrizol as a next-generation cosmetic alternative to Argireline (Acetyl Hexapeptide-8). Targets the neuromuscular junction by antagonizing MuSK-Agrin binding to relax expression lines such as crow's feet and forehead wrinkles.

Synthetic acetylated tetrapeptide developed by Lipotec / Lubrizol for cosmetic anti-puffiness and dark-circle applications around the eyes. Reduces vascular leakage and protein glycation in periorbital tissue. One of the most commercially successful cosmetic peptides for the eye area.

Chimeric pro-apoptotic peptide that selectively destroys white adipose tissue vasculature. Combines a prohibitin/annexin A2-targeting motif with the KLAKLAK pro-apoptotic mitochondrial-disrupting domain. Phase 1 was terminated in 2019 due to nephrotoxicity; remains in research-only use today, frequently discussed in biohacker communities.

A cell-permeable AMPK activator that mimics metabolic effects of exercise. Studied as an "exercise pill" but banned by WADA as a metabolic modulator.

Single-molecule dual GLP-1 and amylin receptor agonist developed by Novo Nordisk. Available in both subcutaneous weekly and oral daily formulations. Phase 2 complete with Phase 3 obesity program starting 2026. Aims to combine the satiety mechanisms of semaglutide and cagrilintide in one peptide.

A modified fragment of human growth hormone designed to isolate fat-burning effects without growth promotion. Completed Phase 2 clinical trials for obesity but was not approved.

Long-acting once-weekly GLP-2 receptor agonist developed by Ironwood Pharmaceuticals (licensed from VectivBio). Phase 3 STARS trial in short bowel syndrome with intestinal failure (SBS-IF) met its primary endpoint; NDA submission planned. Designed as a once-weekly successor to teduglutide's daily dosing.

An EPO-derived peptide that provides tissue protection and neuroprotection without blood cell stimulation. Activates the innate repair receptor.

A cosmetic peptide that reduces expression lines by inhibiting neuromuscular transmission. Known as a topical Botox alternative for anti-aging skincare.

Synthetic 20-amino-acid peptide direct thrombin inhibitor FDA-approved December 2000 for anticoagulation in patients undergoing percutaneous coronary intervention (PCI), particularly those with heparin-induced thrombocytopenia (HIT). Engineered from hirudin, the natural anticoagulant from medicinal leeches.

A synthetic 15-amino acid peptide derived from human gastric juice protein, extensively studied for tissue healing, gastrointestinal protection, and regenerative properties. One of the most researched peptides in regenerative medicine.

12-amino-acid hypothalamic peptide derived from the BRINP2 prohormone, discovered at Stanford University in 2025. Reduces appetite via a novel non-incretin cAMP-PKA-CREB-FOS pathway in the brain. Currently preclinical with Merrifield Therapeutics advancing toward IND. Promises Ozempic-like weight loss without nausea or muscle loss.

Long-acting amylin and calcitonin dual receptor agonist developed by Novo Nordisk for chronic weight management. The amylin component of CagriSema, the most-anticipated next-generation obesity therapy of 2025-2026.

A tetrapeptide that selectively binds to injured brain tissue by targeting tenascin-C and proteoglycan complexes upregulated at injury sites. CAQK shows significant neuroprotective effects and is being developed as a potential first-in-class treatment for traumatic brain injury.

A Khavinson bioregulator tetrapeptide for cardiac support. Targets heart muscle function and myocardial health.

A neuropeptide mixture from porcine brain containing BDNF, NGF, and other neurotrophic factors, approved in Europe/Asia for stroke and dementia.

Synthetic decapeptide GnRH antagonist FDA-approved August 2000 to prevent premature LH surge during controlled ovarian stimulation in IVF cycles. The first GnRH antagonist approved for assisted reproductive technology.

A synthetic GHRH analog with extended half-life, designed to stimulate growth hormone production. Available in DAC (long-acting) and no DAC forms. Often combined with GHRPs for synergistic effects.

A Khavinson tetrapeptide bioregulator for cerebral cortex, promoting neuroprotection and neural repair.

Synthetic stable glucagon analogue with seven amino acid substitutions versus native human glucagon. FDA-approved March 2021 for severe hypoglycemia in patients with diabetes ages 6 and older. The first ready-to-use stable glucagon in autoinjector form.

A cosmetic peptide for skin lightening through tyrosinase inhibition. Used for hyperpigmentation, dark spots, and skin brightening without hydroquinone risks.

Synthetic decapeptide GnRH antagonist FDA-approved December 2008 for advanced hormone-dependent prostate cancer. Achieves immediate testosterone suppression without the initial flare seen with GnRH agonists. Monthly subcutaneous depot injection.

Synthetic D-amino-acid tetrapeptide kappa-opioid receptor (KOR) agonist approved by the FDA in August 2021 for moderate-to-severe pruritus in adults on hemodialysis. The only peripherally-restricted KOR peptide drug — non-addictive and non-mu-opioid.

An extremely potent nootropic peptide derived from angiotensin IV. Works through HGF/c-Met signaling with reported effects millions of times more potent than BDNF.

A neuropeptide that promotes delta wave sleep and modulates stress responses. Research shows effects on sleep quality, stress adaptation, and hormone regulation.

An FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular benefits in the REWIND trial.

Long-acting cAMP-biased GLP-1 receptor agonist developed by Sciwind Biosciences. Approved in China in 2025 for chronic weight management. Once-weekly subcutaneous injection with biased agonism designed to favor cAMP signaling over β-arrestin recruitment.

Elamipretide is a synthetic mitochondria-targeting tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane. FDA-approved in 2025 for Barth syndrome, it stabilizes mitochondrial cristae structure, reduces oxidative stress, and enhances ATP production.

Synthetic 36-amino-acid peptide HIV-1 fusion inhibitor that binds the gp41 envelope protein. FDA-approved March 2003 as the first-in-class entry inhibitor for treatment-experienced HIV-1 infection. A landmark approval in peptide antiviral therapy.

A synthetic tetrapeptide based on the pineal gland peptide epithalamin, studied for its effects on telomerase activation and anti-aging properties. Developed by Russian researcher Vladimir Khavinson.

Cyclic heptapeptide GPIIb/IIIa receptor antagonist derived from a peptide motif in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). FDA-approved May 1998 for acute coronary syndrome and PCI. The first venom-derived peptide approved for cardiovascular therapy.

Synthetic 8-amino-acid D-peptide calcimimetic FDA-approved February 2017 for secondary hyperparathyroidism in adults on hemodialysis. The first peptide calcimimetic and the only intravenous calcium-sensing receptor agonist.

The first FDA-approved GLP-1 agonist (2005), derived from Gila monster venom, pioneering the incretin mimetic drug class for type 2 diabetes.

A myostatin-inhibiting glycoprotein that removes the natural limit on muscle growth. Studied for muscle wasting diseases, muscular dystrophy, and age-related muscle loss.

A senolytic peptide that selectively induces death in senescent cells by disrupting the FOXO4-p53 interaction. Represents a novel approach to targeting cellular aging.

A peptide fragment of human growth hormone containing the lipolytic region. Studied for fat-burning effects without the growth-promoting properties of full GH.

30-amino-acid neuropeptide widely distributed in the central and peripheral nervous systems. Modulates noradrenergic locus coeruleus and serotonergic raphe neurons via three GalR receptor subtypes (GalR1, GalR2, GalR3). Research peptide with significant interest as a target for depression and obesity comorbidity.

Synthetic decapeptide GnRH antagonist FDA-approved July 2000 for prevention of premature LH surges in women undergoing controlled ovarian stimulation for IVF. A direct alternative to cetrorelix in modern antagonist IVF protocols.

A TGF-β family member studied as a potential rejuvenation factor, though research remains controversial.

A naturally occurring tripeptide that modulates over 4,000 genes, promoting wound healing, collagen synthesis, and tissue regeneration.

A naturally occurring copper-bound tripeptide with powerful effects on wound healing, collagen synthesis, and skin regeneration. Declines with age and is widely used in both cosmetic and research applications.

28-amino-acid acylated peptide hormone secreted by stomach X/A-like cells. The only known endogenous orexigenic (appetite-stimulating) hormone in humans. Acts as the natural ligand of the GHSR-1a receptor — the same receptor activated by GHRPs, MK-677, and macimorelin. Research peptide.

One of the most potent growth hormone releasing peptides, GHRP-2 provides strong GH stimulation with moderate appetite effects. Often combined with GHRH analogs for synergistic effects.

One of the first synthetic growth hormone secretagogues, GHRP-6 activates the ghrelin receptor to stimulate robust GH release. Known for significant appetite stimulation due to ghrelin pathway activation.

Long-acting GLP-2 receptor agonist developed by Zealand Pharma for short bowel syndrome (SBS). Twice-weekly subcutaneous dosing. Phase 3 EASE-1 trial showed positive efficacy, but the FDA issued a Complete Response Letter in December 2024 requesting additional clinical data.

Synthetic GnRH identical to the natural hormone. FDA-approved for diagnostic testing and fertility treatment. Stimulates LH and FSH release from the pituitary.

Synthetic decapeptide GnRH (LHRH) agonist FDA-approved December 1989 for advanced prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning. The only GnRH agonist FDA-approved for premenopausal advanced breast cancer. Administered as a 1-month or 3-month subcutaneous depot implant.

The most potent GHRP for growth hormone release, hexarelin also exhibits unique cardioprotective properties. More prone to desensitization than other GHRPs.

Synthetic nonapeptide GnRH (LHRH) agonist delivered via a 12-month subcutaneous implant. FDA-approved 2007 for central precocious puberty (Supprelin LA) and 2004 for advanced prostate cancer (Vantas, US-discontinued 2021). The only annual GnRH agonist implant.

Human Growth Hormone (HGH), also known as somatropin, is a 191-amino acid peptide hormone naturally produced by the pituitary gland. It plays a critical role in growth, metabolism, cell regeneration, and body composition. Recombinant HGH is FDA-approved for multiple medical conditions and serves as the foundation for understanding growth hormone-related peptide research.

The first discovered mitochondrial-derived peptide, humanin provides broad cytoprotective effects against cell death. Studied for neuroprotection in Alzheimer's and metabolic disease.

Synthetic decapeptide bradykinin B2 receptor antagonist FDA-approved August 2011 for acute attacks of hereditary angioedema (HAE) in adults. Self-administered subcutaneous injection that can be used at home for on-demand attack treatment.

A modified form of IGF-1 with enhanced potency and extended half-life. Modifications prevent binding protein sequestration, increasing bioavailability approximately 2-3 fold.

A highly selective growth hormone releasing peptide (GHRP) that stimulates GH release with minimal impact on cortisol and prolactin. Known for its clean side effect profile and synergy with GHRH analogs.

The minimal active fragment of kisspeptin that regulates the reproductive axis. Stimulates GnRH release to control fertility and puberty.

An anti-inflammatory tripeptide from α-MSH that inhibits NF-κB signaling. Studied for inflammatory bowel disease and gut inflammation without tanning effects.

Long-acting somatostatin analogue with SSTR2 and SSTR5 selectivity. FDA-approved August 2007 for acromegaly and December 2014 for gastroenteropancreatic neuroendocrine tumors. The primary alternative to octreotide LAR for chronic somatostatin therapy, with monthly subcutaneous deep injection.

An enkephalin-mimetic cosmetic peptide that promotes muscle relaxation to reduce expression lines. Works through opioid-like receptor activation.

An FDA-approved GnRH agonist used for prostate cancer, endometriosis, and precocious puberty through pituitary desensitization and hormone suppression.

14-amino-acid synthetic peptide guanylate cyclase-C (GC-C) agonist FDA-approved August 2012 for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). One of the highest-revenue peptide drugs globally.

An FDA-approved GLP-1 agonist for type 2 diabetes and weight management. Requires daily dosing. The first GLP-1 approved specifically for obesity treatment.

Once-daily short-acting GLP-1 receptor agonist FDA-approved July 2016 for type 2 diabetes. A 44-amino-acid modified exendin-4 analogue with C-terminal lysine extension. US sales were discontinued in 2023; remains marketed elsewhere as Lyxumia.

The only human cathelicidin antimicrobial peptide, LL-37 provides broad-spectrum antimicrobial activity and immunomodulatory effects. Key component of innate immunity.

Shorter fragments of the full LL-37 antimicrobial peptide that retain biological activity. Easier to synthesize while maintaining antimicrobial and immunomodulatory effects.

Long-acting once-weekly PEGylated prodrug of recombinant human growth hormone using Ascendis Pharma's TransCon linker technology. FDA-approved 2021 for pediatric growth hormone deficiency, expanded July 2025 for adult GHD.

Radiolabeled somatostatin analogue (octreotate conjugated via DOTA chelator to lutetium-177) used as peptide-receptor radionuclide therapy (PRRT) for somatostatin receptor type 2-positive gastroenteropancreatic neuroendocrine tumors. FDA-approved January 2018.

An FDA-approved oral ghrelin agonist for diagnosing adult growth hormone deficiency.

Long-acting peptide-antibody conjugate developed by Amgen for obesity. Combines a GLP-1 receptor agonist peptide with a monoclonal antibody that antagonizes the gastric inhibitory polypeptide receptor (GIPR). Phase 3 MARITIME program initiated 2025; once-monthly subcutaneous injection.

A dual-peptide complex combining collagen-stimulating and anti-inflammatory peptides. One of the most researched anti-aging ingredients in cosmetics.

Long-acting GLP-1 receptor / glucagon receptor dual agonist developed by Innovent Biologics (China) and Eli Lilly. Approved in China by NMPA in 2025 for both chronic weight management (June) and type 2 diabetes (September). The first GLP-1/glucagon dual agonist approved anywhere in the world.

An FDA-approved selective MC1R agonist for erythropoietic protoporphyria. Provides UV-free tanning and photoprotection without the sexual side effects of Melanotan II.

A synthetic melanocortin receptor agonist known for tanning and sexual function effects. Not FDA approved and carries significant safety concerns including potential melanoma risk.

Recombinant analogue of human leptin (147 amino acids) FDA-approved February 2014 for the metabolic complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The only approved leptin replacement therapy.

A splice variant of IGF-1 produced in response to muscle damage. Activates satellite cells to initiate muscle repair. First signal in the muscle regeneration cascade.

A potent, orally active growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without affecting cortisol levels.

A mitochondrial-derived peptide that regulates metabolism through AMPK activation. Studied as an exercise mimetic with effects on insulin sensitivity, fat oxidation, and longevity.

An enhanced anxiolytic peptide analog of tuftsin with superior stability, providing GABA modulation and anxiety relief without benzodiazepine-like side effects.

An enhanced nootropic peptide derived from ACTH(4-10) with superior stability and bioavailability, promoting BDNF expression and cognitive enhancement.

An essential coenzyme that declines with age. Critical for energy metabolism, DNA repair, and sirtuin activation. Target for longevity research.

Synthetic decapeptide GnRH (LHRH) agonist FDA-approved February 1990, delivered as an intranasal spray. Used for endometriosis and central precocious puberty. The only intranasal GnRH agonist on the US market.

36-amino-acid peptide and the most abundant neuropeptide in the mammalian central nervous system. Master regulator of feeding behavior, anxiety, stress resilience, and circadian rhythm via Y1, Y2, Y4, and Y5 receptors. Intranasal NPY is in clinical investigation for PTSD at Mount Sinai.

A skin-lightening peptide that blocks α-MSH at MC1R receptors to reduce melanin production. Works at the receptor level rather than enzyme inhibition.

An FDA-approved somatostatin analog for acromegaly and neuroendocrine tumors, inhibiting growth hormone and various gut hormones.

A 33-amino acid neuropeptide critical for regulating wakefulness, with deficiency causing narcolepsy type 1.

37-amino-acid endogenous gut hormone released from intestinal L-cells postprandially. Naturally activates both the GLP-1 receptor and the glucagon receptor — the template molecule for the entire GLP-1/glucagon dual-agonist class (survodutide, pemvidutide, mazdutide, retatrutide). Research peptide.

The "love hormone" involved in social bonding, reproduction, and maternal behavior. FDA-approved for labor induction and postpartum hemorrhage. Researched for social and psychiatric applications.

A synthetic CNTF-derived peptide that promotes neurogenesis and BDNF release. Designed for blood-brain barrier penetration and cognitive enhancement research.

The original Matrixyl cosmetic peptide — palmitic acid-conjugated procollagen fragment KTTKS. Stimulates collagen and fibronectin synthesis in dermal fibroblasts. Distinct from the more complex Matrixyl 3000 blend; widely used in commercial anti-aging skincare since 2002.

An anti-inflammatory cosmetic peptide that reduces IL-6 production. Component of Matrixyl 3000 complex for anti-aging applications.

Long-acting once-daily PEGylated prodrug of teriparatide (PTH 1-34) using Ascendis Pharma's TransCon linker technology. FDA-approved August 2024 as the first and only treatment for adult chronic hypoparathyroidism.

A Khavinson bioregulator tetrapeptide targeting pancreatic function. Studied for effects on insulin regulation and glucose metabolism.

Cyclohexapeptide multi-receptor somatostatin analogue with 40-fold higher SSTR5 affinity than other SST analogues. FDA-approved December 2012 for Cushing's disease (twice-daily SC) and December 2014 for acromegaly (monthly LAR). The only somatostatin analogue approved for Cushing's disease.

A neurotrophic peptide derived from prosaposin that activates GPR37 receptors. Studied for neuroprotection and cognitive enhancement.

A PEGylated version of MGF with extended half-life for systemic distribution. Trades local action for prolonged activity in research applications.

Pegylated cyclic peptide that inhibits complement component C3, FDA-approved May 2021 for paroxysmal nocturnal hemoglobinuria (PNH) and July 2025 for C3 glomerulopathy. The first approved C3-targeted complement therapy and a key milestone in peptide drug development.

Long-acting balanced GLP-1 / glucagon dual receptor agonist developed by Altimmune. Currently in Phase 3 for metabolic dysfunction-associated steatohepatitis (MASH) and obesity, with FDA Breakthrough Therapy designation. Once-weekly subcutaneous injection.

36-amino-acid gut peptide hormone (and its 34-amino-acid bioactive metabolite PYY 3-36) released from intestinal L-cells postprandially. Acts as a Y2 receptor-selective satiety signal. Long-acting analogues are in clinical development as adjuncts to GLP-1 agonists for obesity.

A Khavinson bioregulator tripeptide designed to support pineal gland function. Studied for effects on melatonin production and circadian rhythm normalization.

16-amino-acid synthetic uroguanylin analogue and guanylate cyclase-C (GC-C) agonist FDA-approved January 2017 for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). pH-dependent activity may produce a milder diarrhea profile than linaclotide.

Synthetic 37-amino-acid amylin analogue FDA-approved March 2005 as an adjunct to mealtime insulin in type 1 and insulin-treated type 2 diabetes. The first amylin-receptor agonist approved for diabetes, foreshadowing the next-generation cagrilintide and amycretin.

An FDA-approved melanocortin receptor agonist that works in the brain to enhance sexual desire and arousal. Marketed as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

A first-in-class triple agonist of GIP, GLP-1, and glucagon receptors showing unprecedented weight loss in clinical trials. Currently in Phase 3 development by Eli Lilly.

Mitochondria-targeting tetrapeptide developed by Stealth BioTherapeutics as a CNS-active successor to elamipretide (SS-31, Forzinity). Phase 1 SAD/MAD studies completed; FDA Orphan Drug Designation for amyotrophic lateral sclerosis (ALS). Crosses the blood-brain barrier to deliver mitochondrial protection in upper motor neurons.

A synthetic anxiolytic peptide derived from tuftsin, approved in Russia for anxiety treatment. Provides anti-anxiety effects without sedation, dependence, or cognitive impairment typical of benzodiazepines.

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. One of the most effective medications for weight loss, available as once-weekly injection or daily oral tablet.

A synthetic nootropic peptide based on ACTH 4-10, approved in Russia for cognitive enhancement and stroke recovery. Known for dramatically increasing BDNF and supporting neuroplasticity.

A GHRH analog consisting of the first 29 amino acids of growth hormone-releasing hormone. Previously FDA-approved, sermorelin stimulates natural GH production while preserving physiological feedback mechanisms.

Selective melanocortin-4 receptor (MC4R) agonist approved for monogenic obesity caused by POMC, PCSK1, or LEPR deficiency, Bardet-Biedl syndrome, and acquired hypothalamic obesity. The first and only approved MC4R agonist for body-weight regulation.

A mitochondrial-derived peptide with potent insulin-sensitizing, anti-diabetic, and neuroprotective properties that declines with age.

A unique mitochondrial-derived peptide with pro-apoptotic properties in cancer cells while protecting normal cells.

An extended 8-amino acid version of Argireline with enhanced SNARE complex inhibition. Used in cosmetics for expression line reduction.

First-in-class activin signaling inhibitor (ActRIIA-Fc fusion protein) approved by the FDA in March 2024 for adults with pulmonary arterial hypertension (PAH, WHO Group 1). The first new mechanism for PAH in over a decade.

Mitochondria-targeting tetrapeptide developed in the Szeto-Schiller laboratory at Cornell. A "sister molecule" to SS-31 (elamipretide / Forzinity) but with a distinct mechanism — promotes mitochondrial respiration without scavenging reactive oxygen species. Currently research-only, with growing interest in mitochondrial biohacker and longevity communities.

11-amino-acid neuropeptide of the tachykinin family that activates the neurokinin-1 (NK1) receptor. Discovered in 1931, it is a master regulator of neurogenic inflammation, pain transmission, mood, and wound healing. Endogenous neuropeptide widely used in research; not a therapeutic drug.

A dual GLP-1/glucagon receptor agonist in Phase 3 trials showing up to 19% weight loss and significant MASH improvement with FDA Breakthrough Therapy designation.

A synthetic peptide mimicking snake venom component waglerin-1. Reduces expression lines by antagonizing nicotinic acetylcholine receptors.

A collagen-boosting peptide that activates the TGF-β pathway to stimulate fibroblast collagen production. Used for improving skin firmness and reducing wrinkles.

A synthetic peptide derived from the active region of Thymosin Beta-4, widely researched for tissue repair, wound healing, and recovery. TB-500 is one of the most popular healing peptides in research communities.

Recombinant GLP-2 (glucagon-like peptide-2) analogue with a single Ala-to-Gly substitution conferring DPP-4 resistance. FDA-approved December 2012 for short bowel syndrome dependent on parenteral support. The first and only commercially available GLP-2 analogue.

Recombinant 34-amino-acid N-terminal fragment of human parathyroid hormone, FDA-approved in 2002 as the first anabolic (bone-building) osteoporosis therapy. Administered as a once-daily subcutaneous injection.

An FDA-approved GHRH analog for treating HIV-associated lipodystrophy. Reduces excess abdominal fat by stimulating natural growth hormone release.

A triple monoamine reuptake inhibitor being developed for obesity. Inhibits serotonin, norepinephrine, and dopamine reuptake to reduce appetite and increase metabolism.

A thymic peptide complex used in Russia for immune system support. Enhances T-cell function and thymic activity, particularly in aging and immunodeficiency.

A Khavinson dipeptide bioregulator for thymus and immune system modulation, approved in Russia as an immunomodulator.

A thymic peptide approved in 35+ countries for hepatitis and immune deficiency. Enhances T-cell function and immune response. One of the most clinically validated immunomodulatory peptides.

A 43-amino acid regenerative peptide that promotes wound healing, tissue repair, and cardioprotection through actin sequestration and stem cell activation. TB-500 is a synthetic fragment containing the active region of this naturally occurring peptide.

The first FDA-approved dual GIP/GLP-1 receptor agonist, producing record-breaking weight loss results. Approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

Synthetic trifluoroacetylated tripeptide developed by Lucas Meyer Cosmetics for anti-aging skincare with a specific focus on cellular senescence and progerin-related skin aging. Suppresses senescence-associated MMP activity and preserves elastin and collagen. Widely used in longevity-focused anti-aging products.

An FDA-approved GnRH agonist that paradoxically suppresses reproductive hormones through continuous administration. Used for prostate cancer, endometriosis, and precocious puberty.

Synthetic analogue of glycine-proline-glutamate (GPE), the N-terminal tripeptide of IGF-1. FDA-approved in March 2023 as the first-ever treatment for Rett syndrome in patients aged 2 years and older.

A Khavinson bioregulator tripeptide for vascular health. Targets endothelial function and blood vessel support.

The shortest known bioactive peptide with anti-aging, immune-modulating, and chromatin-remodeling properties.

A naturally occurring 28-amino acid neuropeptide with vasodilatory, immunomodulatory, and neuroprotective functions. Studied in CIRS and inflammatory conditions.

Modified C-type natriuretic peptide (CNP) analogue approved by the FDA in November 2021 for achondroplasia. The first and only drug ever approved for achondroplasia, the most common genetic form of disproportionate short stature.

Synthetic peptide derived from the venom of the cone snail Conus magus. FDA-approved December 2004 as the first non-opioid intrathecal analgesic for severe chronic pain. Selective N-type voltage-gated calcium channel blocker.

Synthetic macrocyclic peptide complement C5 inhibitor approved by the FDA in October 2023 for generalized myasthenia gravis. The first self-administered subcutaneous peptide therapy for myasthenia gravis and a milestone in macrocyclic peptide drug development.